Please input keywords
top
About Eucure
Eucure Biopharma is a China based innovative biotechnology company with global vision, specializing in developing innovative antibody drugs with independent intellectual property rights. Eucure Biopharma owns a seasoned team with in-depth experience in global clinical development, and is dedicated to providing a comprehensive range of professional services, including clinical medicine, science, clinical operations, regulatory registrations, data management, biostatistics, clinical supply chain, CMC, pharmacology & toxicology, clinical safety and pharmacovigilance. Eucure Biopharma has set up offices in Beijing, Shanghai and the United States according to the company's development strategy. And these branches are responsible for conducting global clinical trials mainly in China, the United States and Australia. Eucure Biopharma owns a clinical development team experienced in comprehensive global and domestic drug development, and has a good relationship network at the operational level of clinical trials in China, the United States and Australia. In addition, our team has the ability to integrate clinical development functions. Eucure Biopharma has the core competitiveness in project strategy, registration affairs (U.S. Food and Drug Administration, and China National Medical Products Administration), clinical study protocol design, efficient and massive clinical operation implementation, and cooperation with KOL/PI. In addition, Eucure Biopharma has built a comprehensive development governance system covering development supervision, standardized operating procedures (SOPs), and systematic supplier assessment and management processes, all of which are designed to ensure patients' safety. Eucure Biopharma is a wholly-owned subsidiary of Biocytogen committed to clinical development. Since its establishment in October 2019, Eucure Biopharma's clinical development team has built robust development pipelines for over ten targets self-developed by Biocytogen. Currently, three R&D products have obtained investigational new drug application (IND) approvals from China NPMA, and two of them have obtained (IND) approvals from U.S. FDA. All three R&D products have entered Phase I clinical trials in Australia, including one entered Phase II in Australia . One of them has entered Phase I clinical trials in China, two R&D products are about to enter Phase I clinical trials in China. All these achievements serve as the best proof of Eucure Biopharma's strength in clinical development.
Development History
2021.01
The first patient screening was completed for Phase I clinical study of YH001 in China.
2020.10
Shanghai Office opened for business.
2020.08
Eucure Biopharma was merged with Biocytogen.
2020.08
YH002 received the IND approval from NMPA.
2020.08
YH001 received the IND approval from NMPA.
2020.07
The first patient screening was completed for Phase I clinical study of YH003 in combination with Junshi Biosciences' PD-1 in Australia.
2020.06
The first patient screening was completed for Phase I clinical study of YH002 in Australia.
2020.05
The first patient screening was completed for Phase I clinical study of YH001 in combination with Junshi Biosciences' PD-1 in Australia.
2020.01
YH002 successfully received the IND approval.
2019.10
The first project YH001 successfully received the IND approval.
2019.10
Established an international clinical development team.
2019.05
Established a subsidiary in Boston.
2018.03
Completed the B round funding from CMBI as the lead-investor and 3E BioVentures as the co-investor.
2017.07
Received A+ round funding from BVCF and SDIC.
2016.12
Received A round funding from BVCF and SDIC.
2016.11
Eucure (Beijing) Biopharma Co., Ltd. (hereinafter referred to as "Eucure Biopharma") was established.
Management Team
Dr. Yuelei Shen
Chief Executive Officer
Dr. Rong Chen
Chief Medical Officer
Dr. Zhihong Li
Chief Registrar and Strategy Officer
Sabrina Wang
Chief Operating Officer
Who we are

Eucure Biopharma is a wholly-owned subsidiary of Biocytogen committed to clinical development.

Biocytogen is an international biotechnology company that develops new drugs based on innovative technology. Biocytogen is committed to becoming the birthplace of global new drugs with the mission of focusing on technological innovation, continuous new drug production, and safeguarding of human health. Biocytogen has established a unique new drug development system covering the whole drug development process by organically integrating the single-cell antibody discovery technology platform, efficient gene editing model development platform, large-scale animal model supply platform, and rapid animal in vivo and in vitro drug efficacy evaluation platform with powerful clinical development capabilities based on the fully human antibody RenMab®, RenLiteTM, and RenNanoTM mice independently developed by Biocytogen with completely independent intellectual property rights. Therefore, Biocytogen successfully transformed into Biotech, and will focus more on development of innovative antibody drugs in the future. As implementation of the large-scale antibody drug development - "Project Integrum", Biocytogen will work with global partners to jointly accelerate the new drug development. Biocytogen is headquartered in Beijing, with branches in Haimen (Jiangsu), Boston, Shanghai. Eucure Biopharma, a wholly-owned subsidiary of Biocytogen, focuses on clinical development.


For more information, please visit https://biocytogen.com